药代动力学
放射性配体
人血清白蛋白
化学
白蛋白
血浆蛋白结合
成纤维细胞活化蛋白
结合位点
药理学
生物化学
医学
癌症
内科学
作者
Kosuke Saito,Hiroyuki Watanabe,Keisei Yamaguchi,Kazuma Nakashima,Masahiro Ono
标识
DOI:10.1021/acs.molpharmaceut.5c00631
摘要
Fibroblast activation protein (FAP) is an attractive biomarker for tumor-targeting radioligands. While [ 68 Ga]Ga-FAPI-46 is a promising FAP-targeting radioligand for cancer diagnosis, clinical application of [ 177 Lu]Lu-FAPI-46 for targeted radionuclide therapy is limited due to its insufficient tumor retention. Albumin binder (ALB) including 4-( p -iodophenyl)butyric acid is widely utilized to improve tumor accumulation of radioligands. In addition, substituted groups in 4-( p -iodophenyl)butyric acid are known to play a significant role in the pharmacokinetics of radioligands. In this study, we newly designed FAPI-46 derivatives (FAPI-46-I, FAPI-46-Br, and FAPI-46-CH 3 ) by incorporating 4-( p -substituted phenyl)butyric acid moieties and studied relationships among structures of ALB moieties, albumin-binding affinities, and pharmacokinetics of FAPI-46 derivatives. The FAP binding affinities of nat In-labeled FAPI-46 derivatives were comparable to that of [ nat In]In-FAPI-46. 111 In-labeled compounds demonstrated different albumin-binding affinities depending on their ALB moieties. Moreover, the difference in ALB moieties of 111 In-labeled compounds influenced their tumor accumulation properties, with [ 111 In]In-FAPI-46-I demonstrating the highest tumor accumulation. These results suggest that the pharmacokinetics of [ 111 In]In-FAPI-46 are modified by ALB moieties, and that [ 111 In]In-FAPI-46-I may be a promising FAP-targeting radioligand.
科研通智能强力驱动
Strongly Powered by AbleSci AI